Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7348317	GALDERMA LABS LP	Aqueous compositions containing metronidazole	Feb, 2022 (1 year, 7 months ago)
US6881726	GALDERMA LABS LP	Aqueous compositions containing metronidazole	Feb, 2022 (1 year, 7 months ago)

Metrogel is owned by Galderma Labs Lp.

Metrogel contains Metronidazole.

Metrogel has a total of 2 drug patents out of which 2 drug patents have expired.

Expired drug patents of Metrogel are:

Metrogel was authorised for market use on 30 June, 2005.

Metrogel is available in gel;topical dosage forms.

Metrogel can be used as once a day topical treatment of the inflammatory lesions of rosacea.

The generics of Metrogel are possible to be released after 21 February, 2022.

Market Authorisation Date: 30 June, 2005

Treatment: Once a day topical treatment of the inflammatory lesions of rosacea

Dosage: GEL;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.01	21 Oct, 2008	1	22 Jul, 2011	21 Feb, 2022	Eligible

Strength	Dosage	Availability
1%	GEL;TOPICAL	Prescription

METROGEL family patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic